References

Adams DA, Edwards RJ, Davies DS & Boobis AR (1997) Specific inhibition of human CYP1A2 using a targeted antibody. Biochem. Pharmacol. 54: 189-197.

Agúndez JAG, Jiménez-Jiménez FJ, Luengo A, Bernal ML, Molina JA, Ayuso L, Vazquez A, Parra J, Duarte J, Coria F, Ladero JM, Alvarez CJ & Benítez J (1995) Association between the oxidative polymorphism and the early onset of Parkinson’s disease. Clin. Pharmacol. Ther. 57: 291-298.

Agúndez JAG, Martínez C, Ladero JM, Ledesma MC, Ramos JM, Martín R, Rodriguez A, Jara C & Benítez J (1994) Debrisoquine oxidation genotype and susceptibility to lung cancer. Clin. Pharmacol. Ther. 55: 10-14.

Aitio A (1978) A simple and sensitive assay of 7-ethoxycoumarin deethylation. Anal. Biochem. 85: 488-491.

Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, Boobis AR, Pelkonen O & Raunio H (1997) Expression and localization of CYP3A4 and CYP3A5 in human lung. Am. J. Respir. Cell. Mol. Biol. 16: 242-249.

Apseloff G, Shepard DR, Chambers MA, Nawoot S, Mays DC & Gerber N (1990) Inhibition and induction of theophylline metabolism by 8-methoxypsoralen: in vivo study in rats and humans. Drug Metab. Dispos. 18: 298-303.

Armeer B & Weintraub RA (1997) Drug interactions with grapefruit juice. Clin. Pharmacokinet. 33: 131-137.

Armstrong M, Daly AK, Cholerton S, Bateman DN & Idle JR (1992) Mutant debrisoquine hydroxylation genes in Parkinson’s disease. Lancet 339: 1017-1018.

Asseffa A, Smith SJ, Nagata K, Gillette J, Gelboin HV & Gonzalez FJ (1989) Novel exogenous heme-dependent expression of mammalian cytochrome P450 using baculovirus. Arch. Biochem. Biophys. 274: 481-490.

Ayesh RA, Idle JR, Ritchie JC, Crothers MJ & Hezel MR (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312: 169-170.

Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE & Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P-4503A and 2C9. Xenobiotica, 25: 261-270.

Barbeau A, Cloutier T, Roy M, Plasse L, Paris S & Poirier J (1985) Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet 30: 1213-1216.

Beaune PH, Kremers PG, Kaminsky LS, de Graeve J, Albert A & Guengerich FP (1986) Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes. Drug Metab. Dispos. 14: 437-442.

Bertz RJ & Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32: 210-258.

Boobis AR (1995) Prediction of inhibitory drug-drug interactions by studies in vitro. In: Pacifici GM & Fracchia GN, (eds.) Advances in drug metabolism in man. Office for the Official Publications of the European Communities, Luxembourg, pp. 513-539.

Boobis AR, McKillop D, Robinson DT, Adams DA & McCormick DJ (1998) Interlaboratoy comparison of the assessment of P450 activities in human hepatic microsomal samples. Xenobiotica 28: 493-506.

Bouchardy C, Benhamou S & Dayer P. (1996) The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Carcer Res. 56: 251-253.

Bourrie M, Meunier V, Berger Y & Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277: 321-332.

Brady JF, Xiao F, Wang MH, Li Y, Ning SM, Gapac JM & Yang CS (1991) Effects of disulfiram on hepatic P4502E1 and other microsomal enzymes and hepatotoxicity in rats. Toxicol. Appl. Pharmacol. 108: 366-373.

Broly F, Libersa C, L’Hermitte M, Becthel P & Dupuis B (1989) Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br. J. Clin. Pharmacol. 28: 29-36.

Brosen K (1993) The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin. Invest. 71: 1002-1009.

Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE & Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45: 1211-1214.

Burke MD, Prough RA & Mayer RT (1977) Characteristics of a microsomal cytochrome P-448-mediated reaction ethoxy-resorufin O-deethylation. Drug Metab. Dispos. 5: 1-8.

Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T & Mayer RT (1985) Ethoxy-, pentoxy-, and benzyloxy-phenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34: 3337-3345.

Caporaso N, DeBaun MR & Rothman N (1995) Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Pharmacogenetics 5: S129-S134.

Cashman JR, Park SB, Yang Z-C, Wrighton SA, Jacob P & Benowitz NL (1992) Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N’-oxide. Chem. Res. Toxicol. 5: 639-646.

Chang TKH, Weber GF, Crespi CL & Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53: 5629-5637.

Chauret N, Gauthier A, Martin J & Nicoll-Griffith DA (1997) In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab. Dispos. 25: 1130-1136.

Cholerton S, Daly AK & Idle JR (1992) The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci. 13: 434-439.

Clarke SE, Ayrton AD & Chenery RJ (1994) Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24: 517-526.

Cribb AE, Spielberg SP & Griffin GP (1995) N4-Hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P450 2C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab. Dispos. 23: 406-414.

Czerwinski M, McLemore T, Gelboin H & Gonzalez F (1994) Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors. Cancer Res. 54: 1085-1091.

Daujat M, Charrasse S, Fabre I, Lesca P, Jounaidi Y, Larroque C, Poellinger L & Maurel P (1996) Induction of CYP1A1 gene by benzimidazole derivatives during Caco-2 cell differentiation. Evidence for an aryl-hydrocarbon receptor-mediated mechanism. Eur. J. Biochem. 237: 642-652.

de Graaf IAM, van der Voort D, Brits JHFG & Koster HJ (2000) Increased post-thaw viability and phase I and II biotransformation activity in cryopreserved rat liver slices after improvement of a fast-freezing method. Drug Metab. Dispos. 28: 1100-1106.

de Groot MJ, Bijloo GJ, Matens BJ, van Acker FAA & Vermeulen NPE (1997) A refined substrate model for human cytochrome P450 2D6. Chem. Res. Toxicol. 10: 41-48.

de Kanter R, Olinga P, Hof I, de Jager M, Verwillegen WA, Slooff MHJ, Koster HJ, Meijer DKF & Groothuis GMM (1998) A rapid and simple method for cryopreservation of human liver slices. Xenobiotica 28: 225-234.

Doecke DJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LM & McManus ME (1991) Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br. J. Clin. Pharmacol. 31: 125-130.

Draper AJ, Madan A & Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch. Biochem. Biophys. 341: 47-61.

Ekins S, Murray GI & Hawksworth GM (1996) Ultrastructural and metabolic effects after vitrification of precision-cut rat liver slices with antifreeze proteins. Cryo. Lett. 17: 157-164.

Ekins S, VandenBranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV & Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J. Pharmacol. Exp. Ther. 286: 1253-1259.

Ekins S, VandenBranden M, Ring BJ & Wrighton SA (1997) Examination of purported probes of human CYP2B6. Pharmacogenetics 7: 165-179.

Eliasson E, Johansson I & Ingelman-Sundberg M (1990) Substrate-, hormone, And cAMP-regulated cothochrome P450 degradation. Proc. Natl. Acad. Sci. U.S.A. 87: 3225-3229.

Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM & Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos. 28: 1222-1230.

Ferrini JB, Pichard L, Domergue J & Maurel P (1997) Long term primary cultures and human hepatocytes. Chem.-Biol. Interact. 107: 31-45.

Fisher CW, Shet MS, Martin-Wixtrom C & Estabrook RW (1992) High-level expression in Escherichia coli of enzymatically active fusion proteins containing the domains of cytochromes P450 and NADPH-P450 reductase flavoprotein. Proc. Natl. Acad. Sci. USA 89: 10817-10821.

Funck-Brentano C, Becquemont L, Leneveu A, Roux A, Jaillon P & Beaune P (1997) Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J. Pharm. Exp. Ther. 280: 730-738.

Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ & Idle JR (1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirements in patients undergoing anticoagulation therapy. Pharmacogenetics 5: 389-392.

Gervot L, Carriere B, Costet P, Cugnenc PH, Berger A, Beaune P & de Waziers I (1996) CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines. Environ. Tox. Pharm. 2: 381-388.

Gill HJ, Thia JF, Kitteringham NR, Pirmohamed M, Back DJ & Park BK (1999) The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. Pharmacogenetics 9: 43-53.

Gillam EMJ, Baba T, Kim B-R, Ohmori S & Guengerich FP (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 305: 123-131.

Gillis JC & Markham A (1997) Irbesartan. Drugs 54: 885-902.

Glöckner R, Steinmetzer P, Drobner C & Muller D (1998) Application of cryopreserved precision-cut liver slices in pharmacotoxicology – principles, literature data and own investigations with special reference to CYP1A1-mRNA induction. Exp. Toxicol. Pathol. 50: 440-449.

Goa KL & Vagstaff AJ (1996) Losartan potassium. Drugs 51: 820-845.

Goldstein JA & de Morais SMF (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299.

Gonzalez FP (1989) The molecular biology of cytochrome P450s. Pharmacol. Rev. 40: 243-288.

Gonzalez FP, Crespi CL & Gelboin HV (1991) cDNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutation Res. 247: 113-127.

Gonzalez FP & Korzekwa KR (1995) Cytochrome P450 expression systems. Ann. Rev. Pharmacol. Toxicol. 35: 369-390.

Grace JM, Kinter MT & Macdonald TL (1994) Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,α-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem. Res. Toxicol. 7: 286-290.

Gu L, Gonzalez FJ, Kalow W & Tang BK (1992) Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2: 73-77.

Gu J, Su T, Chen Y, Zhang QY & Ding X (2000) Expression of biotransformational enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. Toxicol. Appl. Pharmacol. 165: 158-162.

Guengerich, F.P. (1991) Oxidation of toxic and carcinogenic chemical by human cytochrome P450 enzymes. Chem. Res. Toxicol. 4: 391-407.

Guengerich, F.P. (1995a) Human cytochrome P-450 enzymes. In Cytochromes P-450, ed. Ortiz de Montellano PR, pp. 473-535, New York, Plenum.

Guengerich FP (1995b) Cytochromes P450 of human liver. Classification and activity profiles of the major enzymes. In: Pacifici GM & Fracchia GN, (eds.) Advances in drug metabolism in man. Office for the Official Publications of the European Communities, Luxembourg, pp. 179-231.

Guengerich FP (1999) Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39: 1-17.

Guengerich FP, Brian WR, Sari M-A & Ross JT (1991a) Expression of mammalian cytochrome P450 enzymes using yeast-based vectors. Methods Enzymol. 206: 130-145.

Guengerich FP, Kim D-H & Iwasaki M (1991b) Role of human cytochrome P4502E1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4: 168-179.

Guengerich FP & Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4: 391-407.

Guillouzo A, Langouët S, Morel F, Fardel O, Abdel-Razzak Z & Corcos L (1995) The isolated human cell as a tool to predict in vivo metabolism of drugs. In: Pacifici GM & Fracchia GN, (eds) Advances in drug metabolism in man. Office for the Official Publications of the European Communities, Luxembourg, pp. 756-782.

Guo A, Raeissi S, White R & Stevens J (1997) Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab. Dispos. 25: 390-393.

Hakkola J, Pasanen M, Purkunen R., Saarikoski S, Pelkonen O, Mäenpää J, Rane A & Raunio H (1994) Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem. Pharmacol. 48: 59-64.

Halpert JR, Guengerich FP, Bend JR & Correia MA (1994) Selective inhibitors of cytochromes P450. Toxicol. Appl. Pharmacol. 125: 163-175.

Hargreaves MB, Jones B.C. Smith DA & Gescher A (1994) Inhibition of p-nitrophenol hydroxylase in rat liver microsomes by small aromatic and heterocyclic molecules. Drug Metab. Dispos. 22: 806-810.

Harlow GR & Halpert JR (1998) Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc. Natl. Acad. Sci. USA 95: 6636-6641.

Harris JW, Rahman A, Kin B-R, Guengerich FP & Collins JM (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54: 4026-4035.

Heim MH & Meyer UA (1992) Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 14: 49-58.

Heyn H, White R & Stevens JC (1996) Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab. Dispos. 24: 948-954.

Hickman D, Wang J-P, Wang Y & Unadkat JD (1998) Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab. Dispos. 26: 207-215.

Hong J & Yang S (1985) The nature of microsomal N-nitrosodimethylamine demethylase and its role in carcinogen activation. Carcinogenesis 6: 1805-1809.

Idle JR (1981) Hydroxylation phenotype and hepatocellular carcinoma. In: Davis M, Tredger JM & Williams R eds. Drug reactions and the liver. London, Pitman Medical, pp. 313-315.

Inaba T, Jurima M, Mahon WA & Kalow W (1985) In vitro inhibition studies of two isozymes of human liver cytochrome P-450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab. Dispos. 13: 443-448.

Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y & Sugiyama Y (1998a) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 38: 461-499.

Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H & Sugiyama Y (1998b) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharm. Rev. 50: 387-411.

Jefcoate CR (1978) Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. Methods Enzymol. 11: 258-279.

Jeppesen U, Loft S, Poulsen HE & Brøsen K (1996) A fluvoxamine-caffeine interaction study. Pharmacogenetics 6: 213-222.

Johansson I, Lindros KO, Eriksson H & Ingelman-Sundberg M (1990) Transcriprional control of CYP2E1 in the perivenous liver region and during starvation. Biochem. Biophys. Res. Commun. 173: 331-338.

Jorga KM, Fotteler B, Gasser R, Banken L & Birnboeck H (2000) Lack of interaction between tolcapone and tolbutamide in healthy volunteers. J. Clin. Pharmacol. 40: 544-551.

Juvonen RO, Gynther J, Pasanen M, Alhava E & Poso A (2000) Pronounced differences in inhibition potency of lactone and non-lactone compounds for mouse and human coumarin 7-hydroxylases. Xenobiotica 30: 81-92.

Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ & Bertino JS (1998) Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin. Pharmacol. Therap. 64: 257-268.

Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC, Etheredge J & Jorkasky DK (1997) Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin. Pharmacol. Ther. 62: 417-425.

Kim H, Wang RS, Elovaara E, Raunio H, Pelkonen O, Aoyama T, Vainio H & Nakajima T (1997) Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica 27: 657-665.

Kimonen T, Juvonen RO, Alhava E & Pasanen M (1995) The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br. J. Pharm. 114: 832-836.

Kinonen T, Pasanen M, Gynther J, Poso A, Järvinen T, Alhava E & Juvonen R (1995) Competetive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP2A5 and human CYP2A6. Br. J. Pharm. 116: 2625-2630.

Kivistö KT, Griese E-U, Fritz P, Linder A, Hakkola J, Raunio H, Beaune P & Kroemer HK, (1996) Expression of cytochrome P4503A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumors. Naunyn-Schmiedeberg Arch. Pharmacol. 353: 207-212.

Kivistö KT, Lilja JJ, Backman JT & Neuvonen PJ (1999) Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin. Pharmacol. Ther. 66: 448-453.

Kleinbloesem CH, Siepmann M & Kirch W (1995) Hemolysis on intravenous administration of a new calcium antagonist. J. Cardiovasc. Pharmacol. 25: 855-858.

Knodell RG, Hall SD, Wilkinson GR & Guengerich FP (1987) Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther. 241: 1112-1119.

Ko J-W, Desta Z & Flockhart DA (1998) Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab. Dispos. 26: 775-778.

Kobayashi K, Abe S, Nakajima M, Shimada N, Tani M, Chiba K & Yamamoto T (1999) Role of human CYP2B6 in S-mephobarbital N-demethylation. Drug Metab. Dispos. 27: 1429-1433.

Koenigs LL, Peter RM, Thompson SJ, Rettie AE & Trager WF (1997) Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab. Dispos. 25: 1407-1415.

Kono Y, Yang S & Roberts EA (1997) Extended primary culture of human hepatocytes in a collagen gel sandwich system. In Vitro Cell Dev. Biol. Anim. 33: 467-472.

Koop DR (1992) Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J. 6: 724-730.

Koop DR & Cassazza JP (1985) Identification of ethanol-inducible P-450 isozyme 3a as the acetone and acetol monooxygenase of rabbit microsome. J. Biol. Chem. 260: 13607.

Koymans L, Vermeylen NPE, Van Acker SABE, Tecopele JM, Heykaants JJP, Lavrijsen K, Meuldermans W & Kelder GMDO (1992) A predictive model for substrates of cytochrome P-450-debrisoquine (2D6). Chem. Res. Toxicol. 5: 211-219.

Krahenbuhl S, Menafoglio A, Giostra E & Galliano A (1998) Serious interaction between mibefradil and tacrolimus. Transplantation 66: 1113-1115.

Kremers P (1999) Liver microsomes: a convenient tool for metabolism studies but… In: Boobis AR, Kremers P, Pelkonen O & Pithan K (eds.) European symposium on the prediction of drug metabolism in man: progress and problems. Office for Official Publications of the European Communities, pp 38-52.

Kronbach T, Mathys D, Gut J, Catin T & Meyer UA (1987) High-performance liquid chromatographic assay for bufuralol 1’-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal. Biochem. 162: 24-32.

Kronbach T, Mathys D, Umeno M, Gonzalez FJ & Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36: 89-96.

Kuhnz W & Gieschen H (1998) Predicting the oral bioavailability of 19-nortestosterone progestins in vivo from their metabolic stability in human liver microsomal preparations in vitro. Drug Metab. Dispos. 26: 1120-1127.

Kunze KL & Trager WF (1993) Isoform-selective mechanism based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6: 649-656.

Kurz H & Fichtl B (1983) Binding of drugs to tissues. Drug Metab. Rev. 14: 467-510.

Laethem RM, Balazy M, Falck JR, Laethem CL & Koop DR (1993) Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J. Biol. Chem. 268: 12912-12918.

Laine K, Anttila M, Helminen A, Karnani H & Huupponen R (1999) Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. Br. J. Clin. Pharmacol. 47: 249-254.

Leeman T, Transon C, Bonnabry P & Dayer P (1993) A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp. Clin. Res. 19: 189-195.

Leo MA, Lasker JM, Raucy JL, Kim C-I, Black M & Lieber CS (1989) Metabolism of retinol and retinoic acids by human liver cytochrome P450IIC8. Arch. Biochem. Biophys. 269: 305-312.

Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC & Jurima-Romet M (1997) Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem. Biol. Interact. 107: 5-16.

Mäenpää J, Juvonen R, Raunio H, Rautio A & Pelkonen O (1994) Metabolic interactions of methoxsalen and coumarin in human and mice. Biochem. Pharmacol. 48: 1363-1369.

Markham A & Goa KL (1997) Valsartan. Drugs 54: 299-311.

Martínez C, Agúndez JAG, Gervasini G, Martín R & Benítez J (1997) Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics 7: 85-93.

Maurel P (1996) The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Adv. Drug Del. Rev. 22: 105-132.

Mays DC, Camisa C, Cheney P, Pacula DM, Nawoot S & Gerber N (1987) Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. Clin. Pharmacol. Ther. 42: 621-626.

McClellan KJ & Balfour JA (1998) Eprosartan. Drugs 55: 713-718.

McClellan KJ & Goa KL (1998) Candesartan cilexetil. Drugs 56: 847-869.

McKinnon RA, Hall PM, Quattrochi LC, Tukey RH & McManus ME (1991) Localisation of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology 14: 848-856.

McManus ME, Burgess WM, Veronese ME, Hugget A, Quattrochi LC & Tukey RH (1990) Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocycloc amine mutagens by human cytochromes P450. Cancer Res. 50: 3367-3376.

Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, Guengerich FP & Shimada T (1993) Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab. Dispos. 21: 1048-1056.

Minoletti C, Dijols S, Dansette PM & Mansuy D (1999) Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: Application to the design of a specific substrate of CYP2C18. Biochemistry 38: 7828-7836.

Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J & Cantilena LR (1990) Torsades de pointes occurring in association with terfenadine use. JAMA 264: 2788-2790.

Morel F, Beaune PH, Ratanasavanh D, Flinois JP, Yang CS, Guengerich FP & Guillouzo A (1990) Expression of cytochrome P450 enzymes in cultured human hepatocytes. Eur. J. Biochem. 191: 437-444.

Mullins ME, Horowithz BZ, Linden DH, Smith GW, Norton RL & Stump J (1998) Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 280: 157-158.

Murray M & Reidy GF (1990) Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev. 42: 85-101.

Nakajima M, Yamamoto T, Nunoya K-I, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T & Kuroiwa Y (1996a) Characterization of CYP2A6 involved in 3’-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277: 1010-1015.

Nakajima M, Yamamoto T, Nunoya K-I, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N & Kuroiwa Y (1996b) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 24: 1212-1217.

Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC & Nebert DW (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1-42.

Newton DJ, Wang RW & Lu AYH (1994) Cytochrome P-450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23: 154-158.

Nies A & Spielberg SP (1996) Principles of therapeutics, in Goodman & Gilman’s The Pharmacological Basis of Therapeutics (Wonsiewicz MJ & McCurdy P eds.) pp 43-62, McGraw-Hill, New York, USA.

Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ & Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283: 46-58.

Oscarson M, Gullstén H, Rautio A, Bernal ML, Sinues B, Dahl M-L, Stengård JH, Pelkonen O, Raunio H & Ingelman-Sundberg M (1998) Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett. 438: 201-205.

Pacifici GM & Viani A (1992) Methods of determining plasma and tissue binding of drugs: Pharmacokinetic consequences. Clin. Pharmacokinet. 23: 449-468.

Park YH, Kullberg MP & Hinsvark ON (1984) Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. J. Pharmacol. Sci. 73: 24-29.

Park KS, Sohn DH, Veech RL & Song BJ (1993) Translational activation of ethanol-inducible cytochrome P450 (CYP2E1) by isoniazid. Eur. J. Pharmacol. 248: 7-14.

Pasanen M & Pelkonen O (1994) The expression and environmental regulation of P450 enzymes in human placenta. Crit. Rev. Toxicol. 24: 211-229.

Patten C, Thomas PE, Guy R, Lee M, Gonzalez FJ, Guengerich FP & Yang CS (1993) Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem. Res. Toxicol. 6: 511-518.

Pelkonen O & Breimer DD (1994) Role of environmental factors in the pharmacokinetics of drugs: Considerations with respect to animal models, P-450 enzymes, and probe drugs. In (Welling PG & Balant LP eds.) Handbook of Experimental Pharmacology, vol 110, pp 289-332, Springer-Verlag, Berlin, Germany.

Pelkonen O, Kaltiala EH, Larmi TKI & Kärki NT (1974) Cytochrome P-450-linked monooxygenase system and drug-induced spectral interactions in human liver microsomes. Chem.-Biol. Interactions 9: 205-216.

Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A & Raunio H (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28: 1203-1253.

Pelkonen O, Rautio A, Raunio H & Pasanen M (2000) CYP2A6: a human coumarin 7-hydroxylase. Toxicology 144: 139-147.

Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP & Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450IIE1. Chem. Res. Toxicol. 3: 566-573.

Peyronneau MA, Renaud JP, Truan G, Urban P, Pompon D & Mansuy D (1992) Optimization of yeast-expressed human liver cytochrome-P450 3A4 catalysic activities by coexpressing NADPH-cytochrome P450 reductase and cytochrome β 5. Eur. J. Biochem. 207: 109-116.

Proppe DG, Hoch OD, McLean AJ & Visser KE (1995) Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporin A in renal transplant patients with stable graft function. Br. J. Clin. Pharmacol. 39: 337-338.

Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, Reider PJ, Lin JH & Baillie TA (1999) Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations. Br. J. Clin. Pharmacol. 47: 291-298.

Racha JK, Rettie AE & Kunze KL (1998) Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry 37: 7407-7419.

Rane A, Wilkinson GR & Shand DG (1977) Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther. 200: 420-424.

Rasmussen BB, Mäenpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J & Brosen K (1995) Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br. J. Clin. Pharmacol. 39: 151-159.

Rasmussen BB, Nielsen TL & Br∅sen K (1998) Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. Eur. J. Clin. Pharmacol. 54: 735-740.

Raunio H, Pasanen M, Mäenpää J, Hakkola J & Pelkonen O. (1995) In: Pacifici GM & Fracchia GN, (eds) Advances in drug metabolism in man. Office for the Official Publications of the European Communities, Luxembourg, pp. 234-287.

Raunio H, Syngelmä T, Pasanen M, Juvonen R, Honkakoski P, Kairaluoma MA, Sotaniemi E, Lang MA & Pelkonen O (1988) Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat and mouse. Biochem. Pharmacol. 37: 3889-3895.

Raunio H, Valtonen J, Honkakoski P, Lang MA, Ståhlberg M, Kairaluoma MA, Rautio A, Pasanen M & Pelkonen O (1990) Immunodhemical detection of human liver cytochrome P450 forms related to phenobarbital-inducible forms in the mouse. Biochem. Pharmacol. 40: 2503-2509.

Relling MV, Aoyama T, Gonzalez FJ & Meyer UA (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252: 442-447.

Rendic S & Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29: 413-580.

Renwick AB, Watts PS, Edwards RJ, Barton PT, Guyonnet I, Price RJ, Tredger JM, Pelkonen O, Boobis AR & Lake BG (2000) Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos. 28: 1202-1209.

Rettie AE, Korzekwa R, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ & Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-450 2C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5: 54-59.

Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping. Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem. Pharmacol. 57: 465-480.

Ronis MJJ, Lindros KO & Ingelman-Sundberg M (1996) The CYP2E subfamily. (Ioannides C & Parke DV eds.) pp. 211-239, CRC Press, Boca Raton, USA.

Salonpää P, Hakkola J, Pasanen M, Pelkonen O, Vähäkangas K, Battula N, Nouso K & Raunio H (1993) Retrovirus-mediated stable expression of human CYP2A6 in mammalian cells. Eur. J. Pharmacol. 248: 95-102.

Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS & Shader RI (1995) N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J. Pharmacol. Exp. Ther. 275: 592-597.

Schuetz JD, Kauma S & Guzelian PS (1993) Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J. Clin. Invest. 92: 1018-1024.

Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R & Davis DS (1990) Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. 29: 651-663.

Shimada T, Yamazaki H, Mimura M, Inui Y & Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423.

Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV & Korzekwa KR (1994) Activation of CYP 3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33: 6450-6455.

Siepmann M & Kirch W (2000) Drug-drug interactions of new active substances: mibefradil example. Eur. J. Clin. Pharmacol. 56: 273.

Siepmann M, Kleinbloesem C & Kirch W (1995) The interaction of the calcium antagonist Ro 40-5967 with digoxin. Br. J. Clin. Pharmacol. 39: 491-496.

Skett P, Tyson C, Guillouzo A & Maier P (1995) Report on the international workshop on the Usu of human in vitro liver preparations to study drug metabolism in drug development. Biochem. Pharmacol. 50: 280-285.

Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM, Sturman SG, Schapira AHV, Willian AC, Spurr NK & Wolf CR (1992) Debrisoquine hydroxylase gene polymorpism and susceptibility to Parkinson’s disease. Lancet 339: 1375-1377.

Sohn OS, Ischizaki H, Yang CS & Fiala ES (1991) Metabolism of azoxymethane, methylazoxymethanol and N-nitrosodimethylamine by cytochrome P450IIE1. Carcinogenesis 12: 127-131.

Song B-J, Matsunaga T, Hardwick JP, Park SS, Veech RL, Yang CS, Gelboin HV & Gonzalez FJ (1987) Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat. Mol. Endocrinol. 1: 542-547.

Sonnichsen DS, Lie O, Schuetz EG, Schuetz JD, Pappo A & Relling MV (1995) Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther. 275: 566-575.

Spoendlin M, Peters J, Welker H, Bock A & Thiel G (1998) Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients. Nephrol. Dial. Transplant. 13: 1787-1791.

Stevens JC, White RB, Hsu SH & Martinet M (1997) Human liver CYP2B6-catalyzed hydroxylation of RP 73401. J. Pharmacol. Exp. Ther. 282: 1389-1395.

Streetman DS, Bertino JS & Natziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10: 187-216.

Stresser DM & Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab. Dispos. 27: 517-525.

Strobl GR, von Kreudener A, Stöckigt J, Guengerich FP & Wolff T (1993) Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modelling and inhibition studies. J. Med. Chem. 36: 1136-1145.

Strom S, Pisarov LA, Dorko K, Thompson MT, Schuetz JD & Schuetz EG (1996) Use of human hepatocytes to study P450 gene induction. Methods Enzymol. 272: 388-401.

Stubbins MJ, Harries LW, Tarbit MH & Wolf CR (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6: 429-439.

Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang Z-Y, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ & Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6: 341-349.

Tang C, Shou M, Mei Q, Rushmore TH & Rodrigues AD (2000) Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J. Pharmacol. Exp. Ther. 293: 453-459.

Tarrus E, Cam J, Roberts DJ, Spickett RGW, Geldran E & Segura J (1987) Accumulation of caffeine in healthy volunteers treated with furafylline. Br. J. Clin. Pharmacol. 23: 9-18.

Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH & Miners JO (1994) Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics 4: 281-284.

Terelius Y & Ingelman-Sundberg M (1986) Metabolism of n-pentane by ethanol-inducible cytochrome P450 in liver microsomes and reconstituted membranes. Eur. J. Biochem. 161: 303-308.

Thummel KE, Kharasch ED, Podoll T & Kunze K (1993) Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab. Dispos. 21: 350-357.

Tiano HF, Wang RL, Hosokawa M, Crespi C, Tindall KR & Langenbach R (1994) Human CYP2A6 activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): mutational specificity in the gpt gene of AS52 cells. Carcinogenesis 15: 2859-2866.

Ueng Y-F, Kuwabara T, Chun Y-J & Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36: 370-381.

Varhe A, Olkkola KT & Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 56: 601-607.

Venkatakrishnan K, von Moltke LL & Greenblatt DJ (1999) CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor. Drug Metab. Dispos. 27: 1519-1522.

Vickers A, Ferrero J, Fisher R & Brendel K (1995) Xenobiotic metabolism in precesion-cut dynamic organ cultured human liver slices. In: Pacifici GM & Fracchia GN, (eds) Advances in drug metabolism in man. Office for the Official Publications of the European Communities, Luxembourg, pp. 682-753.

von Moltke LL, Greenblatt DJ, Court MG, Duan SX, Harmatz JS & Shader RI (1995) Inhibition of alprazolam and desipramine hycrosylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressnats. J. Clin. Psychopharmacol. 15: 125-131.

von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE & Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 276: 370-379.

von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS & Shader RI (1996) Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. Clin. Pharmacol. 36: 783-791.

von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS & Shader RI (1998) In vitro approaches to predicting drug interactions in vivo. Biochem. Pharmacol. 55: 113-122.

Wacher VJ, Wong S, Wong HT & Benet LZ (1996) Contribution of CYP3A to selegiline metabolism in rat and human liver microsomes. In: ISSX Proceedings 10, 351.

Wandel C, Kim RB, Guengerich FP & Wood AJJ (2000) Miberadil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab. Dispos. 28: 895-898.

Wang RW, Newton DJ, Liu N, Atkins WM & Lu AYH (2000) Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos. 28: 360-366.

Wang RW, Newton DJ, Scheri TD & Lu AYH (1997) Human cytochrome P450 3A4-catalyzed testosterone 6β -hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab. Dispos. 25: 502-507.

Waxman DJ, Ko A & Walsh C (1983) Regioselectivity and stereoselectivity of androgen hydroxylation catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J. Biol. Chem. 258: 11937-11947.

Waxman DJ, Lapeson DP, Aoyama T, Gelboin HV, Gonzalez FJ & Korzekwa K (1991) Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 290: 160-166.

White RE (2000) High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu. Rev. Pharmacol. Toxicol. 40: 133-157.

Wikberg T, Vuorela A, Ottoila P & Taskinen J (1993) Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab. Dispos. 21: 81-92.

Wrighton SA & Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22: 1-21.

Wrighton SA, Stevens JC, Becker GW & VandenBranden M (1993a) Isolation and characterization of human liver cytochrome P450 2C19: Correlation beween 2C19 and S-mephenytoin 4’-hydroxylation. Arch. Biochem. Biophys. 306: 240-245.

Wrighton SA, VandenBranden M, Stevens JC, Shipley LA, Ring FJ, Rettie AE & Cashman JR (1993b) In vitro methods for assesing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 25: 453-484.

Yamano S, Nhamburo PT, Aoyama T, Meyer UA, Inaba T, Kalow W, Gelboin HV, McBride OW & Gonzalez FJ (1989) cDNA cloning and sequence and cDNA-directed expression of human P450IIB1: Identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 28: 7340-7348.

Yamazaki H, Inoue K, Turvy CG, Guengerich FP & Shimada T (1997) Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab. Dispos. 25: 168-174.

Yamazaki H, Inui Y, Yun CH, Guengerich FP & Shimada T (1992) Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13: 1789-1794.

Yang CS, Tu YY, Koop DR & Coon MJ (1985) Metabolism of nitrosamines by purified rabbit liver cytochrome P-450 isozymes. Cancer Res. 45: 1140-1145.

Yin H, Orcarson M, Johansson I, Yue Q-Y, Dahl M-L, Tabone M, Arinco S, Albano E & Ingelman-Sundberg M (1997) Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol. Pharmacol. 51: 370-376.

Yuan R, Parmelee T, Balian JD, Uppoor RS, Ajayi F, Burnett A, Lesko LJ & Marroum P (1999) In vitro metabolic interaction studies: Experience of the Food and Drug Administration. Clin. Pharmacol. Ther. 66: 9-15.

Yun CH, Shimada T & Guengerich FP (1991) Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol. 40: 679-685.